Mirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosedFC
Farallon Capital Management
Activity from announced rounds
Activity in this selectionUnited States · Jan 31, 2026 · Jan 1, 2026
Farallon Capital Management is the investment manager identified by Encoded Therapeutics and HiBob, with Farallon also used as a short name.
Recorded funding activity
Encoded develops precision gene therapies for neurological disorders. HiBob supplies the Bob people-management platform, while Mirador develops medicines for inflammatory and fibrotic diseases. Their financing events retain the same manager identity without collapsing individual funds.
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $555M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed